Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.

doi:10.1016/j.phrs.2023.106859

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.

Pharmacological research - 1 Aug 2023

Zapata-Cobo Paula, Salvador-Martín Sara, Velasco Marta, Palomino Laura M, Clemente Susana, Segarra Oscar, Moreno-Álvarez Ana, Fernández-Lorenzo Ana, Pérez-Moneo Begoña, Montraveta Montserrat, Sánchez Cesar, Tolín Mar, Loverdos Inés, Fobelo María Jesús, Navas-López Victor Manuel, Magallares Lorena, García-Romero Ruth, Sánchez-Hernández José Germán, Rodríguez Alejandro, Bossacoma Ferrán, Balboa María Jesús, Salcedo Enrique, Sanjurjo-Sáez María, López-Fernández Luis A

Abstract excerpt

Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore, the aim of the study was to analyze the usefulness of biomarkers of response to anti-TNFs in pediatric IBD (pIBD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child

Share to Helicobacter pylori-related gastroenterology studies

Share to Immunodeficiency and Autoimmune Disorders

Share to Inflammatory Bowel Disease

Share to Inflammatory Bowel Diseases

Share to Polymorphism, Single Nucleotide

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed

Identifiers

PMID: 37473877
DOI: 10.1016/j.phrs.2023.106859

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.PMID 37473877Read ↗

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studySemantic proximity Read ↗

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.Semantic proximity Read ↗

Pharmacogenetic biomarkers of response in Crohn's disease.Semantic proximity Read ↗

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.Semantic proximity Read ↗

Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy.Semantic proximity Read ↗

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.Semantic proximity Read ↗

Genetic and genomic predictors of anti-TNF response.Semantic proximity Read ↗

IL10 rs1800896 Genetic Variant Predicts Biochemical Remission in Inflammatory Bowel Disease Patients Undergoing Biologic Therapy.Semantic proximity Read ↗

Novel Associations Between Major Histocompatibility Complex and Pediatric-onset Inflammatory Bowel Disease.Semantic proximity Read ↗

The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity Read ↗

Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.